Market Overview

UPDATE: Bank of America Downgrades Momenta Pharmaceuticals to Underperform on Valuation

Related MNTA
CombiMatrix's Pre-Implantation Genetic Screening Approval Highlights Today's Pre-Market Biotech Roundup
Benzinga's Top Initiations
Momenta Pharmaceuticals Announces Positive Results for Humira Biosimilar (GuruFocus)

Bank of America downgraded Momenta Pharmaceuticals (NASDAQ: MNTA) from Neutral to Underperform and maintained a $14.00 price objective.

Bank of America analyst Sumant S. Kulkarni wrote, "While fundamentals remain similar and we are not changing our model, we are downgrading MNTA from Neutral to Underperform as the stock is trading around our DCF-based PO of $14. We note our model already includes value for generic Copaxone (tough to genericize), and $400mn for future milestones from the Baxter biosimilars partnership (product specifics largely unknown). As a result, we believe the stock, which is up ~18% YTD, already reflects these positives and could underperform other stocks in our coverage cluster. "

Momenta Pharmaceuticals closed at $13.86 on Monday.

Latest Ratings for MNTA

Nov 2016Aegis CapitalInitiates Coverage OnHold
Oct 2016BarclaysUpgradesEqual-WeightOverweight
Sep 2016Maxim GroupDowngradesHoldSell

View More Analyst Ratings for MNTA
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Downgrades Analyst Ratings


Related Articles (MNTA)

View Comments and Join the Discussion!